Immunic’s (IMUX) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital restated their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a $17.00 price target on the stock. IMUX has been the topic of several other reports. StockNews.com lowered shares of Immunic from a “hold” rating to […]
D. Boral Capital restated their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a $17.00 price target on the stock. IMUX has been the topic of several other reports. StockNews.com lowered shares of Immunic from a “hold” rating to […]
